Jenkins John Kenneth 4
4 · Corbus Pharmaceuticals Holdings, Inc. · Filed Jun 11, 2026
Research Summary
AI-generated summary of this filing
Corbus (CRBP) Director John K. Jenkins Sells 4,800 Shares
What Happened
Director John K. Jenkins reported a sale of 4,800 shares of Corbus Pharmaceuticals (CRBP) on June 10, 2026. The weighted-average sale price was $7.91 per share (range $7.71–$7.97), for total proceeds of approximately $37,986. This was a sale (not a purchase) and therefore generally viewed as routine insider selling unless tied to other company events.
Key Details
- Transaction date: June 10, 2026; Form 4 filed June 11, 2026 (within the normal reporting window).
- Shares sold: 4,800; weighted-average price: $7.91; price range: $7.71–$7.97.
- Proceeds: ~$37,986.
- Holdings after transaction: not specified in the excerpt; filing notes reported holdings include 3,800 unvested RSUs subject to prior vesting schedule (see footnote).
- Notable footnotes: transaction was executed under a Rule 10b5-1 trading plan adopted March 11, 2026; the reported price is a weighted average and detailed per-price breakdown is available on request.
Context
The sale was made under a pre-established 10b5-1 plan, which typically means trades were scheduled in advance and are less indicative of near-term insider sentiment. Sales are common insider activity and, by itself, do not necessarily signal a change in outlook for the company.
Insider Transaction Report
- Sale
Common Stock, par value $0.0001 per share
[F1][F2][F3]2026-06-10$7.91/sh−4,800$37,986→ 3,833 total
Footnotes (3)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule as previously reported.